AUS
NZ
UK
CA
USA
IND
Kaplan Fox & Kilsheimer LLP has initiated an investigation into Fulcrum Therapeutics, Inc. (NASDAQ:FULC) for possible securities law breaches. This inquiry follows the company's June 1, 2026, announcement to discontinue its pociredir program for sickle cell disease treatment, which caused a dramatic drop in its stock price. The law firm is calling on investors who incurred losses and anyone with pertinent information to come forward.
Key Points
- Kaplan Fox & Kilsheimer LLP is probing Fulcrum Therapeutics, Inc. (NASDAQ:FULC) for potential securities violations.
- Fulcrum revealed on June 1, 2026, the termination of its pociredir program for sickle cell disease due to FDA concerns over its benefit-risk profile.
- The stock plunged 51.09%, falling from $6.42 per share on June 1, 2026, to $3.14 per share on June 2, 2026, a loss of $3.28 per share.
- The investigation arises from FDA apprehensions about increased malignancy risks linked to PRC2 inhibitor treatments, highlighted by the global withdrawal of Tazverik in March 2026.
Kaplan Fox & Kilsheimer LLP Announces Inquiry Into Fulcrum Therapeutics
Kaplan Fox & Kilsheimer LLP, a prominent national securities litigation firm headquartered in New York, declared on July 27, 2026, that it is investigating Fulcrum Therapeutics, Inc. for potential violations of securities laws. This action follows significant developments at the biopharmaceutical firm that led to a steep decline in its stock value.
The firm is examining possible breaches by Fulcrum Therapeutics and is actively seeking investors who have suffered losses as well as individuals possessing information relevant to the probe. Interested parties can reach out to the firm via email or phone using the contact details provided in the announcement.
Discontinuation of Pociredir Program Amid FDA Regulatory Concerns
On June 1, 2026, after market close, Fulcrum Therapeutics announced it would cease development of its pociredir program aimed at treating sickle cell disease. The decision was driven by heightened concerns from the U.S. Food and Drug Administration regarding the drug's benefit-risk balance in addressing this rare hematological condition.
According to Fulcrum's disclosure, recent end-of-phase meeting minutes with the FDA revealed the agency's worries stemmed from an unexpectedly high incidence of secondary hematologic malignancies linked to Tazverik (tazemetostat), another PRC2 inhibitor that was withdrawn globally in March 2026. After Fulcrum submitted additional data, the FDA concluded that any pharmacological agent targeting the PRC2 complex carries a comparable malignancy risk regardless of the specific subunit targeted. This determination effectively blocked any regulatory path forward for pociredir's clinical development.
Sharp Stock Price Decline Following Program Termination
The market reacted swiftly to Fulcrum Therapeutics' announcement, with the stock price dropping from $6.42 per share at close on June 1, 2026, to $3.14 per share on June 2, 2026—a 51.09% decrease, equating to a $3.28 loss per share in a single trading day.
This significant price movement underscores investor concerns about the company's pipeline and regulatory outlook. The pociredir program was a key clinical asset for Fulcrum, a company focused on developing small molecules to enhance the lives of patients with rare blood disorders. The steep decline indicates the market had heavily valued the program, and its discontinuation raises questions about the company’s future development and revenue potential.
FDA’s Comprehensive Review of PRC2 Inhibitor Safety
The FDA's decision regarding PRC2 inhibitors marks a critical development extending beyond Fulcrum's pociredir program. The agency's stance that any therapeutic targeting the PRC2 complex carries an equivalent malignancy risk signals a class-wide safety concern that may affect other firms working on similar treatments.
This broader FDA assessment followed the global market withdrawal of Tazverik (tazemetostat), a competing PRC2 inhibitor, in March 2026 due to secondary hematologic malignancies. Fulcrum’s additional submissions failed to change the FDA’s position, reflecting a cautious regulatory approach toward PRC2-targeting therapies.
Kaplan Fox’s Expertise in Securities Litigation
Kaplan Fox & Kilsheimer LLP, founded in 1956, is a nationally acclaimed law firm specializing in complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Over more than five decades, the firm has prosecuted securities, antitrust, and consumer protection cases in federal and state courts across the U.S.
The firm has secured over $10 billion in recoveries for clients and class members, including a $2.425 billion recovery for Bank of America shareholders in In re Bank of America, the largest ever under Section 14(a) of the Securities Exchange Act; an $800 million recovery for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors; and a $475 million settlement in In re Merrill Lynch. Kaplan Fox has been recognized by Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon.
Focus on Both Institutional and Individual Investors
Kaplan Fox has a long history of representing public pension funds, institutional investors, businesses, and individual shareholders in high-stakes securities litigation. The firm’s experience positions it well to pursue claims on behalf of both large institutional clients and individual investors who suffered losses linked to alleged securities violations.
The firm is currently seeking Fulcrum Therapeutics investors who incurred losses and individuals with relevant information about the company or the events surrounding the stock decline and program discontinuation. Multiple contact methods, including email and telephone, are provided for potential claimants.
Company Profile and Therapeutic Focus
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing small molecule therapies aimed at improving outcomes for patients with rare hematological disorders. The discontinuation of the pociredir program removes a significant clinical asset from its pipeline.
Investors may be concerned about how this program halt affects Fulcrum’s overall development pipeline, financial health, and long-term prospects in a competitive therapeutic sector. The announcement does not detail other pipeline programs or the company’s financial capacity to continue development efforts.
Details on the Investigation and Investor Implications
The probe by Kaplan Fox focuses on whether Fulcrum Therapeutics or its management violated securities laws in connection with company disclosures or conduct. Such investigations typically assess if investors received timely, accurate, and complete material information.
The timing of the June 1, 2026, announcement—after market close—is noted as relevant. The investigation may explore whether the company was aware of FDA concerns or safety signals related to PRC2 inhibitors before this date and if earlier disclosure was warranted.
Information for Fulcrum Therapeutics Investors
Investors holding Fulcrum Therapeutics shares at the time of the June 1, 2026 announcement who suffered losses might have potential claims linked to this securities investigation. The law firm encourages those affected or with pertinent information to come forward.
Investors should review all company disclosures, including press releases, SEC filings, and regulatory communications if available. The company did not disclose prior challenges or FDA concerns about pociredir before the June 1 announcement. Potential claimants are advised to consult securities counsel to understand their rights and options regarding possible claims related to Fulcrum Therapeutics stock losses.
